Lian­Bio was found­ed to tack­le a big mis­sion: to take the in-li­cens­ing strat­e­gy that’s been pop­u­lar­ized in Chi­na over the past decade and su­per­charge it with rich glob­al con­nec­tions and a cre­ative ap­proach to deal­mak­ing. Now, the high-pro­file Per­cep­tive start­up has bagged $325 mil­lion to go even big­ger as a pub­lic com­pa­ny. The biotech has priced its IPO at $16 a share — for more than 20 mil­lion shares — giv­ing it a ful­ly di­lut­ed val­ue of about $1.88 bil­lion, ac­cord­ing to Bloomberg . Since en­ter­ing the lime­light last Au­gust, Lian­Bio has inked a slate of deals show­cas­ing just how...